giardiasis

Secnidazole (PM-185184) is a second-generation 5-nitroimidazole antimicrobial that is structurally related to other 5-nitroimidazoles including [DB00916] and [DB00911], but displays improved oral absorption and longer terminal elimination half-life than antimicrobial agents in this class [A27210]. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria and protozoa.

Paromomycin binds specifically to the RNA oligonucleotide at the A site of bacterial 30S ribosomes, thereby causing misreading and premature termination of translation of mRNA and inhibition of protein synthesis followed by cell death. Paromomycin Sulfate (Aminosidine sulfate) is the sulfate salt form of paromomycin, a structural derivative of neomycin, an aminoglycoside antibiotic with amebicidal and bactericidal effects against predominantly aerobic gram-negative bacteria.

Secnidazole hemihydrate (RP-14539), an orally ingestible azole derivative antibiotic and imidazole-based Serratia marcescens virulence suppressor, analogously inhibits acylhomoserine lactones, mitigating Pseudomonas aeruginosa pathogenicity through quorum sensing (QS) disruption. This compound exhibits broad-spectrum antimicrobial efficacy against numerous anaerobic Gram-negative and Gram-positive bacteria in vitro. Its therapeutic application spans the study and treatment of ailments including amoebiasis, giardiasis, and bacterial vaginitis [1] [2] [3].